NCT06945978 Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer (mirPANC 2)
| NCT ID | NCT06945978 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Benedito Mauro Rossi |
| Condition | Pancreatic Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-01-21 |
| Primary Completion | 2027-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2025-01-21 with a primary completion date of 2027-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is being conducted to better understand how pancreatic cancer behaves during treatment and how we can improve methods for monitoring disease progression. The research aims to determine whether small molecules present in the blood, called miRNAs, can help doctors assess whether the treatment is working or needs adjustment. With this, we hope to make cancer monitoring less invasive and more precise, allowing patients to receive more personalized and effective treatments.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with metastatic PDAC; * Patients who will start treatment with FOLFIRINOX; * 18 years or older; * Who agree to participate in the study by signing the Informed Consent Form; Exclusion Criteria: * Patients who have previously undergone chemotherapy, whether neoadjuvant, adjuvant, or any prior first-line treatment; * Patients who do not meet the minimum criteria to receive the proposed regimen, such as those with hyperbilirubinemia, those who are not candidates due to age or performance status deterioration;
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06945978 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06945978 currently recruiting?
Yes, NCT06945978 is actively recruiting participants. Contact the research team at camila.farias@bp.org.br for enrollment information.
Where is the NCT06945978 trial being conducted?
This trial is being conducted at São Paulo, Brazil.
Who is sponsoring the NCT06945978 clinical trial?
NCT06945978 is sponsored by Benedito Mauro Rossi. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.